Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients

Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer

(2016) Guillemette Bernadou et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients

(2015) Eirini Panoilia et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer

(2014) Valérie F. Cosson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study

(2014) Axel Grothey et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

(2013) J M Jürgensmeier et al.   BRITISH JOURNAL OF CANCER

Influence ofFCGRTgene polymorphisms on pharmacokinetics of therapeutic antibodies

(2013) Christophe Passot et al.   mAbs

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

(2012) C. Muller et al.   BLOOD

Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon

(2012) Jing Li et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor

(2012) V. Gouilleux-Gruart et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

(2011) Martin Bergstrand et al.   AAPS Journal

Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients

(2011) N. Azzopardi et al.   CLINICAL CANCER RESEARCH

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Nathanael L. Dirks et al.   CLINICAL PHARMACOKINETICS

An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics

(2010) David Ternant et al.   THERAPEUTIC DRUG MONITORING

Evaluation of different tests based on observations for external model evaluation of population analyses

(2009) Karl Brendel et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Target-mediated drug disposition model: relationships with indirect response models and application to population PK–PD analysis

(2009) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Generalized Maximally Selected Statistics

(2008) Torsten Hothorn et al.   BIOMETRICS

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20

(2008) D. Dayde et al.   BLOOD

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

(2008) Jian-Feng Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY